Your submission is now in Draft mode.

Once it's ready, please submit your draft for review by our team of Community Moderators. Thank you!

Submit Essay

Once you submit your essay, you can no longer edit it.

Pending

This content now needs to be approved by community moderators.

Submitted

This essay was submitted and is waiting for review.

Paxlovid to be given EUA by FDA

Question

From the AP,

Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joined the race for an easy-to-use medication to treat the coronavirus.

Currently most COVID-19 treatments require an IV or injection. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to OK it.

Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible, after independent experts recommended halting the company’s study based on the strength of its results. Once Pfizer applies, the FDA could make a decision within weeks or months.

When will Paxlovid be given an EUA from the FDA?

This question resolves positively on the date during which Paxlovid (also known under PF-07321332, referenced in this article or any product containing PF-07321332 receives an Emergency Use Authorization (EUA) or full approval from the FDA for treating COVID-19.

Make a Prediction

Prediction

Note: this question resolved before its original close time. All of your predictions came after the resolution, so you did not gain (or lose) any points for it.

Note: this question resolved before its original close time. You earned points up until the question resolution, but not afterwards.

Current points depend on your prediction, the community's prediction, and the result. Your total earned points are averaged over the lifetime of the question, so predict early to get as many points as possible! See the FAQ.